The China hepatitis therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD 5.235 billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The hepatitis market especially that of hepatitis B is having great demand in the Chinese geography and about one-third of the people suffering from this belongs to China only. With such a surge in the demand, it is expected that 6 new HBV drugs are expected to be developed in China and eight other major markets by 2028.
The increasing prevalence of hepatitis cases in China along with the promising pipeline of hepatitis drugs and the increasing government attention and initiatives encouraging the patients in the adoption of hepatitis drugs in China. The introduction of generic versions of HCV drugs has changed the market dynamics across the world. With more people being able to afford the generic versions, the usage rates of its drugs are expected to grow rapidly over the next few years and as the accessibility of these drugs is a major issue among the low-income group, the generic cases are a savior when it comes to the treatment of hepatitis in China.
Infectious causes are further subdivided into viral, parasitic, and bacterial among which viral is the most common one.
Autoimmune causes are further subdivided into Alcoholic, Toxic, and drug-induced as well as Non- alcoholic fatty liver disease.
It is a chronic disease caused by an abnormal immune response against liver cells.
Genetic causes of hepatitis include alpha-1-antitrypsin deficiency, hemochromatosis, and Wilson’s disease and are hereditary.
It is characterized by reduced blood flow to the liver because of shocks, vascular inefficiency, or heart failure.